GW

GW Vitek CO.,LTD.

Develops research antibodies and distributes scientific instruments for life science researchers.

036180 | KO

Overview

Corporate Details

ISIN(s):
KR7036180008
LEI:
Country:
South Korea
Address:
서울특별시 금천구 벚꽃로 244 1101호(가산동, 벽산디지털밸리5차), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GW Vitek CO., LTD. is a biotechnology company that provides comprehensive solutions and products for the life sciences research market. The company operates through two primary segments: a Bio division focused on the development, manufacturing, and sale of research antibodies, and a Scientific division that distributes a wide range of scientific instruments and laboratory equipment. Its portfolio includes products for imaging, chromatography, metabolic analysis, and general laboratory use. By collaborating with global partners, GW Vitek aims to deliver innovative and optimal solutions to support the entire research process for scientists and research institutions. The company was formerly known as A-Frontier Co Ltd.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
M&A Activity
기타경영사항(자율공시) (회생회사 지더블유바이텍 주식회사 M&A 공고)
Korean 10.7 KB
2025-09-05 00:00
Legal Proceedings Report
[기재정정]회생절차개시결정
Korean 13.0 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.5 KB
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.8 MB
2025-08-06 00:00
Legal Proceedings Report
[기재정정]회생절차개시결정
Korean 12.6 KB
2025-07-04 00:00
Share Issue/Capital Change
[기재정정]감자결정(자회사의 주요경영사항)
Korean 19.2 KB
2025-06-10 00:00
Share Issue/Capital Change
감자결정(자회사의 주요경영사항)
Korean 14.6 KB
2025-06-04 00:00
Legal Proceedings Report
[기재정정]회생절차개시결정
Korean 12.2 KB
2025-05-27 00:00
Regulatory News Service
불성실공시법인지정
Korean 7.7 KB
2025-05-26 00:00
Legal Proceedings Report
[기재정정]회생절차개시결정
Korean 12.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-29 00:00
Regulatory News Service
불성실공시법인지정예고 (공시번복 2건)
Korean 6.3 KB
2025-04-10 00:00
Delisting Announcement
기타시장안내 (상장폐지 관련 이의신청서 접수 및 개선기간 부여)
Korean 3.9 KB
2025-04-10 00:00
Delisting Announcement
주권매매거래정지기간변경 (개선기간 부여)
Korean 5.2 KB

Automate Your Workflow. Get a real-time feed of all GW Vitek CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GW Vitek CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GW Vitek CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

REGENXBIO Inc. Logo
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
United States of America
RGNX
Rein Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.
United States of America
RNTX
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel
REKA
Relay Therapeutics, Inc. Logo
Developing precision medicines for oncology & genetic diseases by analyzing protein motion.
United States of America
RLAY
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America
RVMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.